Haematology

2020 ◽  
pp. 307-362
Author(s):  
Charlotte Frise ◽  
Sally Collins
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Fetal Development ◽  
Biochemical Markers ◽  
Physiological Changes ◽  
Antithrombotic Drugs ◽  
Pregnancy And Lactation ◽  
Potential Risks ◽  
Haematological Disorders ◽  
In Pregnancy

This chapter begins by describing the normal haematological and physiological changes that occur in pregnancy, and biochemical markers at different trimester stages. It then covers the diagnosis, management, and complications for a range of haematological disorders, which may either pre-exist (such as sickle cell disease, thalassaemia, and other inherited conditions) or develop in pregnancy, including their potential risks to fetal development. Blood products and antithrombotic drugs in both pregnancy and lactation are described.

scholarly journals Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline

2021 ◽  
Author(s):  
Eugene Oteng‐Ntim ◽  
Sue Pavord ◽  
Richard Howard ◽  
Susan Robinson ◽  
Laura Oakley ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
British Society ◽  
Cell Disease ◽  
In Pregnancy

Sickle cell disease in pregnancy

2019 ◽  
Vol 29 (3) ◽  
pp. 61-69
Author(s):  
Kanda Rogers ◽  
Neerujah Balachandren ◽  
Moji Awogbade ◽  
Jemma Johns
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cell Disease ◽  
In Pregnancy

Sickle cell disease in pregnancy

2008 ◽  
Vol 18 (10) ◽  
pp. 272-278 ◽  
Author(s):  
Eugene Oteng-Ntim ◽  
Apryll R. Chase ◽  
Jo Howard ◽  
Nina Khazaezadeh ◽  
Elizabeth N. Anionwu
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cell Disease ◽  
In Pregnancy

Modern Management of Sickle Cell Disease in Pregnancy

1974 ◽  
Vol 67 (4) ◽  
pp. 426-430 ◽  
Author(s):  
JOSEPH H. BELLINA ◽  
JOHN N. BICKERS
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Cell Disease ◽  
Modern Management ◽  
In Pregnancy

Manganese in pregnancy and breastfeeding

2015 ◽  
Author(s):  
Sir Peter Gluckman ◽  
Mark Hanson ◽  
Chong Yap Seng ◽  
Anne Bardsley
Keyword(s):  
Antioxidant Enzymes ◽  
Breast Milk ◽  
Maternal Health ◽  
Fetal Development ◽  
Essential Element ◽  
Mixed Diet ◽  
Disease States ◽  
Neurotoxic Effects ◽  
Pregnancy And Lactation ◽  
In Pregnancy

Manganese is both an essential element and a potent neurotoxin. It is involved in cellular metabolic processes and is a component of antioxidant enzymes. Uptake and efflux of manganese is tightly regulated, as both deficiency and excess can result in disease states. Manganese has essential functions in maternal health and fetal development, and in healthy women adequate amounts can be obtained from a mixed diet of grains, cereals, and fruits. Supplements containing manganese should be used with caution, as excess intake can have neurotoxic effects on the developing brain. Maternal intake in pregnancy and lactation is not likely to be a worry in most cases, as transfer of manganese to the fetus and into breast milk is limited.

scholarly journals Interleukin-6 in pregnancy with sickle cell disease

2019 ◽  
Vol 41 (4) ◽  
pp. 298-302 ◽  
Author(s):  
Manuela Freire Hazin Costa ◽  
Leuridan Cavalcante Torres ◽  
Marina Cadena da Matta ◽  
Aderson da Silva Araújo ◽  
Ariani Impieri Souza
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Interleukin 6 ◽  
Cell Disease ◽  
In Pregnancy

scholarly journals Perinatal Use of Melatonin for Offspring Health: Focus on Cardiovascular and Neurological Diseases

2019 ◽  
Vol 20 (22) ◽  
pp. 5681 ◽  
Author(s):  
Chien-Ning Hsu ◽  
Li-Tung Huang ◽  
You-Lin Tain
Keyword(s):  
Fetal Development ◽  
Animal Studies ◽  
Neurological Diseases ◽  
Later Life ◽  
Developmental Programming ◽  
Biologically Active ◽  
Pregnancy And Lactation ◽  
Health And Disease ◽  
Offspring Health ◽  
In Pregnancy

Cardiovascular and neurological diseases can originate in early life. Melatonin, a biologically active substance, acts as a pleiotropic hormone essential for pregnancy and fetal development. Maternal melatonin can easily pass the placenta and provide photoperiodic signals to the fetus. Though melatonin uses in pregnant or lactating women have not yet been recommended, there is a growing body of evidence from animal studies in support of melatonin as a reprogramming strategy to prevent the developmental programming of cardiovascular and neurological diseases. Here, we review several key themes in melatonin use in pregnancy and lactation within offspring health and disease. We have particularly focused on the following areas: the pathophysiological roles of melatonin in pregnancy, lactation, and fetal development; clinical uses of melatonin in fetal and neonatal diseases; experimental evidence supporting melatonin as a reprogramming therapy to prevent cardiovascular and neurological diseases; and reprogramming mechanisms of melatonin within developmental programming. The targeting of melatonin uses in pregnancy and lactation will be valuable in the prevention of various adult chronic diseases in later life, and especially cardiovascular and neurological diseases.

Sign in / Sign up

Export Citation Format

Share Document